Sarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Thursday morning, Benzinga reports. Cantor Fitzgerald currently has a $128.00 price objective on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on the company. Citigroup upped their target price on Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a buy rating in a report on Thursday, February 29th. Mizuho upped their price objective on shares of Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a buy rating in a research note on Wednesday, February 14th. Needham & Company LLC reissued a buy rating and set a $166.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. Evercore ISI upped their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an in-line rating in a research report on Tuesday, February 20th. Finally, BMO Capital Markets began coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They set an outperform rating and a $170.00 price objective on the stock. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $160.60.

Sarepta Therapeutics Trading Up 2.3 %

SRPT stock traded up $3.03 during trading on Thursday, hitting $133.66. The company had a trading volume of 1,196,284 shares, compared to its average volume of 876,130. The firm has a market capitalization of $12.63 billion, a P/E ratio of 1,215.09 and a beta of 0.95. The company has a quick ratio of 3.45, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $159.89. The company has a 50 day simple moving average of $125.63 and a 200-day simple moving average of $110.81.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company’s quarterly revenue was up 63.1% compared to the same quarter last year. During the same period last year, the company posted ($1.44) earnings per share. As a group, research analysts forecast that Sarepta Therapeutics will post 2.14 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Bilal Arif sold 2,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.84, for a total value of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares in the company, valued at approximately $3,457,550.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $123.25, for a total value of $1,848,750.00. Following the sale, the director now owns 22,840 shares in the company, valued at $2,815,030. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Bilal Arif sold 2,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the transaction, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock worth $2,739,419 over the last 90 days. 7.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after acquiring an additional 243,180 shares during the period. Capital International Investors increased its stake in shares of Sarepta Therapeutics by 160.0% in the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock valued at $457,221,000 after purchasing an additional 2,917,797 shares in the last quarter. Avoro Capital Advisors LLC raised its holdings in Sarepta Therapeutics by 7.9% in the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after purchasing an additional 319,444 shares during the period. Wellington Management Group LLP boosted its position in Sarepta Therapeutics by 5.6% during the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after purchasing an additional 217,810 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $80,697,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.